NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

according to § 12 in BioInvent International AB's Articles of Association.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in **BioInvent International AB (publ)**, Reg. No. 556537-7263 at the Extraordinary General Meeting on December 1, 2026. The voting right is exercised in accordance with the below marked voting options.

BioInvent International AB (publ) at hand no later than November 27, 2026, kindly before 4.00 pm. CET.

Shareholder	**Personal identity number/registration number**

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorized to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	**E-mail**

For further instructions, see the next page.

Instructions to vote in advance by post:

- Complete the information above.
- Select the preferred voting options below.
- Print, sign and send the form in original to BioInvent International AB, Ideongatan 1, SE-223 70 Lund, Sweden, att: Stefan Ericsson. A completed and signed form may also be submitted electronically and shall be sent to stefan.ericsson@bioinvent.com.
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign.
- If the shareholder is a legal entity, a copy of a registration certificate or a corresponding document for the legal entity shall be enclosed together with the form. A power of attorney shall be enclosed if the shareholder votes in advance by proxy.

Please note that a shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this are included in the notice convening the meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The form, together with any enclosed authorization documentation, shall be received by BioInvent International AB no later than November 27, 2026. An advance vote can be withdrawn up to and including the same time by contacting the company via e-mail to stefan.ericsson@bioinvent.com, or by mail to BioInvent International AB, Ideongatan 1, SE-223 70 Lund, Sweden, att: Stefan Ericsson.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. A shareholder who has voted in advance also has the possibility to participate in the meeting room, provided that notification to attend the meeting room has been made in accordance with the instructions in the notice. If a shareholder has voted in advance, and thereafter participates at the Extraordinary General Meeting in person or by proxy, the advance vote is still valid unless the shareholder participates in a vote during the meeting. If the shareholder during the meeting chooses to participate in a vote, the vote cast will replace the previously submitted advance vote in the relevant decision point(s).

Please note that the advance vote does not constitute a notification to attend the meeting room in person or through an authorized representative. Instructions for shareholders who wish to attend the meeting room in person or through an authorized representative is included in the notice convening the Extraordinary General Meeting.

For complete proposals regarding the items on the agenda, kindly refer to the notice convening the meeting and the company's website.

For information on how your personal data is processed, see the integrity policy that is available at www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Advance vote

Extraordinary General Meeting in BioInvent International AB (publ)
on December 1, 2026

The options below comprise, if not otherwise stated in the form, the proposals submitted by the board of directors, which are included in the notice convening the Extraordinary General Meeting.

2. Election of Chairperson of the meeting Yes ☐ No ☐
3. Preparation and approval of the voting list Yes ☐ No ☐
5. Determination of compliance with the rules of convocation Yes ☐ No ☐
6. Approval of the agenda Yes ☐ No ☐
7. Resolution to amend the articles of association Yes ☐ No ☐
8. Approval of the Board of Directors' resolution on a new issue of shares Yes ☐ No ☐
9. Shareholder proposals from Van Herk Investments B.V.
9a. Establishment of the number of members of the Board of Directors Yes ☐ No ☐
9b. Establishment of fees for members of the Board of Directors Yes ☐ No ☐
9c. Election of members of the Board of Directors Yes ☐ No ☐